Predictive Technology Group (Predictive Technology Group) LT-Debt-to-Total-Asset : 0.05 (As of Mar. 2021)

View and export this data going back to 2007. Start your Free Trial

What is Predictive Technology Group LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Predictive Technology Group's long-term debt to total assests ratio for the quarter that ended in Mar. 2021 was 0.05.

Predictive Technology Group's long-term debt to total assets ratio increased from Mar. 2020 (0.04) to Mar. 2021 (0.05). It may suggest that Predictive Technology Group is progressively becoming more dependent on debt to grow their business.

Predictive Technology Group LT-Debt-to-Total-Asset Historical Data

The historical data trend for Predictive Technology Group's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Predictive Technology Group LT-Debt-to-Total-Asset Chart

Predictive Technology Group Annual Data

Trend

Aug06

Aug07

Jun16

Jun17

Jun18

Jun19

Jun20

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.01

0.07

Predictive Technology Group Quarterly Data
	Nov07	Feb08	May08	Jun16	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.04	0.07	0.10	0.04	0.05

Predictive Technology Group LT-Debt-to-Total-Asset Calculation

Predictive Technology Group's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Jun. 2020 is calculated as

LT Debt to Total Assets (A: Jun. 2020 )	=	Long-Term Debt & Capital Lease Obligation (A: Jun. 2020 )	/	Total Assets (A: Jun. 2020 )
	=	5.571	/	83.842
	=	0.07

Predictive Technology Group's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2021 is calculated as

LT Debt to Total Assets (Q: Mar. 2021 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2021 )	/	Total Assets (Q: Mar. 2021 )
	=	3.325	/	66.959
	=	0.05

Predictive Technology Group (OTCPK:PRED) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Predictive Technology Group LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Predictive Technology Group's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Predictive Technology Group (Predictive Technology Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Predictive Technology Group Inc (OTCPK:PRED) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

2735 Parleys Way, Suite 205, Salt Lake City, UT, USA, 84109

Website

https://www.predtechgroup.com

Predictive Technology Group Inc (PRx) is a biotechnology company. It develops, commercializes, acquires and invests in technologies engaged in novel molecular diagnostic and therapeutic products in healthcare. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing proprietary extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The company's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. It generates most of its revenues from HCT/Ps segment.